Wesfarmers reported H1 FY2026 results for the six months ended 31 December 2025, with revenue of AUD 24.21bn (+3.1%) and earnings before interest and tax of AUD 2.49bn (+8.4%). Net profit after tax rose to AUD 1.60bn (+9.3%), while basic earnings per share increased to 141.4 cents (+9.3%). Operating cash flows were AUD 2.49bn (-3.3%) and cash realisation was 99%. The board declared a fully franked interim dividend of 102 cents per share (+7.4%) and said the group also paid a capital management distribution of AUD 1.50 per share, totalling AUD 1.70bn. Management said profit growth was supported by Bunnings, Kmart Group and WesCEF, with productivity initiatives helping offset cost pressures. WesCEF benefited from a positive contribution from its lithium business; the Covalent Lithium joint venture’s refinery was completed below cost estimates, produced high-quality lithium hydroxide during commissioning, and ramp-up plans were extended to address intermittent odour issues, with excess spodumene concentrate sold profitably. Officeworks’ earnings were impacted by costs tied to a transformation program, Wesfarmers Health delivered higher earnings led by Priceline Pharmacy sales growth, and the group highlighted increased use of AI and new partnerships with Microsoft and Google Cloud. On sustainability metrics, TRIFR improved to 9.6 and Scope 1 and 2 (market-based) emissions were 400 ktCO2e (down from 554 ktCO2e).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wesfarmers Ltd. published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.